![]() ![]() We are happy that this agreement with Horizon will enable us to broadcast our technology to a larger audience,” added Christian Thirion, Managing Director of Sirion Biotech. It is a natural step forward to complement Horizon’s drug discovery services and products with Sirion Biotech’s RNAiONE technology, and I am confident that this partnership will provide researchers with optimal integrated solutions for translational genomics. “Horizon is well respected in the industry as a leading translational genomics company. The high silencing efficiency ensured by RNAiONE gives researchers confidence in their functional genomics investigations.” “Issues surrounding knock-down efficiency and the associated phenotypic variation have led to inconsistent results. Jon Moore, VP, Oncology, Horizon Discovery. ![]() “Gene over-expression and knockdown studies are important to both basic and preclinical research, helping to determine the specific roles of genes and potentially leading to the discovery of novel targets for new drugs,” said Dr. ![]() These will be available as transduction ready lentivirus particles or as plasmids. Horizon will also be making available over 125 off-the-shelf RNAiONE-validated shRNAs and over 70 cDNA overexpression constructs. Inducible knock-down and over-expression systems are also available, offering a valuable tool for functional gene analysis and to help deal with the adaptive capacity of cells. The platform is being made available through Horizon as a custom service that delivers a shRNA sequence, transduction-ready lentivirus, or a treated knock-down cell pool. Sirion’s RNAiONE platform is a validation system that reliably produces shRNAs with a gene-silencing efficiency often greater than 90%. Short hairpin RNA (shRNA) has become a staple of the research community for silencing genes, but identifying the most effective shRNA sequence to provide the greatest level of gene suppression often presents a problem. Through this partnership, Horizon now offers a broad spectrum of gene modulation technologies ranging from stable shRNA knockdown and cDNA overexpression systems to the ability to edit endogenous genes via rAAV, ZFN, and CRISPR platforms. Under the terms of this agreement, Horizon’s customers can now access Sirion’s highly efficient RNAiONE custom shRNA development services, as well as Sirion’s off-the-shelf validated shRNA and cDNA over-expression reagents. Horizon Discovery also announced it has signed a supply and distribution agreement with Sirion Biotech GmbH. This marketing and distribution agreement will help make our products accessible to a much broader range of customers active in the translational genomics field,” added Dr. “We are delighted that a company of Horizon’s reputation and commercial reach is recognizing the potential of our Haploid Gene Trap Mutant Collection. We anticipate announcing further partnerships in the future as we continue to broaden our product offering to meet the needs of our customers.” “The addition of the Haplogen cell line products to our offering supports our growth strategy and is highly complementary to our current product portfolio, including our X-MAN range of diploid isogenic cell lines. “Horizon’s mission is to give scientists access to high-value products and services that address their research needs,” commented Dr. For-profit customers will be able to access the cell-line bank by signing an annual limited-use label license, whilst academic customers will be able to access an unlimited term license and will receive a greater than 90% discount. Haplogen’s Haploid Gene Trap Mutant Collection is the largest haploid cell line bank available, and comprises over 9,400 mutant clones, affecting over 3,700 human genes and an additional 1,600 inducible clones covering 1,100 genes. Haploid cellular models offer a biologically relevant system for in vitro genetic analyses of molecular, cellular, and developmental events in various cell lineages. This agreement represents the first time Horizon will be distributing another company’s products, recognizing Horizon’s past success in penetrating the global model cell lines market. Under the terms of the agreement, customers can now access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. Horizon Discovery recently announced it has signed a worldwide distribution agreement with Haplogen GmbH, with immediate effect.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |